Risk factors associated with the conversion of meticillin-resistant Staphylococcus aureus colonisation to healthcare-associated infection

Journal of Hospital Infection

Volumn 79, Issue 3, 2011, Pages 194-197

  Harinstein, L ^a   Schafer, J ^b   D'Amico, F ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c St Margaret Memorial Hospital   (United States)

Author keywords

Colonisation; Healthcare associated infection; Meticillin resistant Staphylococcus aureus; Risk factors

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CYCLOSPORIN; ETANERCEPT; HISTAMINE H2 RECEPTOR ANTAGONIST; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTON PUMP INHIBITOR; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CARRIER; BACTERIUM CULTURE; BALLOON CATHETER; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG UTILIZATION; FEMALE; HEALTH CARE ASSOCIATED INFECTION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION; INFECTION RISK; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NUTRITIONAL STATUS; PERIPHERAL VASCULAR DISEASE; RISK FACTOR; RISK REDUCTION; STAPHYLOCOCCUS INFECTION; WOUND;

AGED; AGED, 80 AND OVER; CARRIER STATE; CASE-CONTROL STUDIES; CATHETERIZATION, CENTRAL VENOUS; CROSS INFECTION; FEMALE; HOSPITALIZATION; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PREVALENCE; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS;

EID: 80053330681     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2011.03.017     Document Type: Article

References (18)

1. Kuehnert M.J., Kruszon-Moran D., Hill H.A., et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2002-2002. J Infect Dis 2006, 193:172-179.
2. Von Eiff C., Becker K., Machka K., Stammer H., Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001, 344:11-16.
3. Miles A.A., Williams R.E.O., Clayton-Cooper B. The carriage of Staphylococcus (ptogenes) aureus in man and its relation to wound infection. J Pathol Bacteriol 1944, 56:513-524.
4. Corbella X., Dominguez M.A., Pujol M., et al. Staphylococcus aureus nasal carriage as a marker for subsequent staphylococcal infections in intensive care unit patients. Eur J Clin Microbiol Infect Dis 1997, 16:351-357.
5. Coello R., Glynn J.R., Gaspar C., Picazo J.J., Fereres J. Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. J Hosp Infect 1997, 37:39-46.
6. Robicsek A., Beaumont J.L., Peterson L.R. Duration of colonization with methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2009, 48:910-913.
7. Huang S.S., Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003, 36:281-285.
8. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
9. Klevens R.M., Morrison M.A., Nadle J., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
10. Perl T.M., Cullen J.J., Wenzel R.P., et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002, 346:1871-1877.
11. van Rijen M.M., Bonten M., Wensel R.P., Kluytmans J.A. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J Antimicrob Chemother 2008, 61:254-261.
12. Garcia A.M., Villa M.V., Escudero M.E., et al. Use of nasal mupirocin for Staphylococcus aureus: effect on nasal carriers and nosocomial infections. Biomedica 2003, 23:173-179.
13. Nardi G., Di Silvestre A.D., De Monte A., et al. Reduction in gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin. Eur J Emerg Med 2001, 8:203-214.
14. Muller A., Talon D., Potier A., Belle E., Cappelier G., Bertrand X. Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units. Crit Care 2005, 9:R246-250.
15. Jones J.C., Rogers T.J., Brookmeyer P., et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007, 45:541-547.
16. Walker E.S., Vasquez J.E., Dula R., Bullock H., Sarubbi F.A. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective?. Infect Control Hosp Epidemiol 2003, 24:342-346.
17. Donowitz L.G., Wenzel R.P., Hoyt J.W. High risk of hospital-acquired infection in the ICU patient. Crit Care Med 1982, 10:355-357.
18. Klevens R.M., Edwards J.R., Tenover F.C., et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US Hospitals, 1992-2003. Clin Infect Dis 2006, 42:389-391.